Peptide Tools to Study Coronaviruses
About Coronaviruses
The coronavirus family comprises several viruses such as
- Severe acute respiratory syndrome coronavirus (SARS-CoV)
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- Middle East respiratory syndrome-related coronavirus (MERS)
- Common cold coronaviruses HCoV 229E, OC43, HKU1 and NL63
- Various animal coronaviruses
Coronaviruses have a positive-sense single-stranded RNA genome and characteristic spikes on their surface, which create an image reminding of the solar corona.
The spikes are composed of Spike proteins (S protein) which contain two subunits. Subunit S1 forms the spike head with the receptor binding domain (RBD). Subunit S2 forms the stem and enables fusion with the host cell. S1 proteins are the most variable components of the virus as they are responsible for host cell specificity.
Spike protein, membrane protein (M) and envelope protein (E) are anchored in the viral envelope, a lipid bilayer.
JPT's Peptide Tools to Study Coronaviruses
JPT is an expert for manufacturing a wide variety of synthetic peptide formats for research and clinical applications in the development of immunotherapy and vaccines and immune monitoring. Our researchers constantly develop new products for well-known infectious diseases such as HIV, TB or HBV as well as newly emerging diseases such as MERS, SARS and COVID-19.
We have broadened our portfolio of coronavirus related products beyond SARS-CoV-2, including products and services for SARS-CoV, MERS-CoV and common cold viruses CoV 229E, OC43, HKU1 and NL63.
References with Coronavirus Peptide Tools
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
Corbett et al, New England J of Med (2020)
Presence of SARS-CoV-2 reactive T cells in COVID-19 Patients and Healthy Donors
Braun et al, Nature (2020)
Single-shot Ad26 Vaccine Protects against SARS-CoV-2 in Rhesus Macaques
Mercado et al, Nature (2020)
Safety and Immunogenicity of a Modified Vaccinia Virus Ankara Vector Vaccine Candidate for Middle East Respiratory Syndrome: an Open-Label, Phase 1 Trial
Koch et al, Lancet (2020)
Data, Reagents, Assays and Merits of Proteomics for SARS-CoV-2 Research and Testing
Zecha et al, Mol Cell Proteomics (2020)
Self-amplifying RNA SARS-CoV-2 Lipid Nanoparticle Vaccine Candidate Induces High Neutralizing Antibody Titers in Mice
McKay et al, Nature 2020
The Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for MERS-CoV Infection as Identified by Temporal Kinome Analysis
Kindrachuk et al, Antimicrob Agents Chemother. (2014)
Further references
Check our list of products,
click and go.
News Highlights
-
JPT’s SARS CoV-2 Products Deliver Meaningful Results!
(Aug 2020) -
SARS-COV-2 Spike & NCAP Mutations as PepMix™ Peptide Pools
(Aug 2020) -
Study SARS CoV-2 Cross Reactive T-Cells with EMPS-Peptides from Endemic HCoV’s
(Jul 2020) -
SARS COV-2 Mass Spec Reference Kit Released!
(Jul 2020) -
Mission Completed! Purified SARS-CoV-2 PepMixes™ & Peptide Arrays
(Jun 2020)
--> Read more News
Downloads
Quality Assurance
All production is performed according to ISO 9001:2015 standards